Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine Retinal Safety in Healthy Volunteers
NCT02658435Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of tafenoquine in vivax malaria, sponsored by GSK. Primary endpoint: Proportion of participants with retinal changes from Baseline in Central subfield thickness at 90 days. Started Feb 2016; status: completed.
02
Drugs
tafenoquine
03
Conditions
vivax malaria
Beyond the preview
Go deeper on NCT02658435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658435.